Promoting Global Research Excellence in Severe Sepsis (PROGRESS): Lessons from an International Sepsis Registry

被引:119
作者
Beale, R. [1 ]
Reinhart, K. [2 ]
Brunkhorst, F. M. [2 ]
Dobb, G. [3 ]
Levy, M. [4 ]
Martin, G. [5 ]
Martin, C. [6 ]
Ramsey, G. [7 ]
Silva, E. [8 ]
Vallet, B. [9 ]
Vincent, J. -L. [10 ]
Janes, J. M. [11 ]
Sarwat, S. [11 ]
Williams, M. D. [11 ]
机构
[1] St Thomas Hosp, Guys & St Thomas NHS Fdn Trust, Adult Intens Care Unit, London SE1 7EH, England
[2] Univ Jena, Dept Anesthesiol & Intens Care, Jena, Germany
[3] Royal Perth Hosp, Sch Med & Pharmacol, Perth, WA, Australia
[4] Brown Univ, Sch Med, Providence, RI 02912 USA
[5] Emory Univ, Div Pulm Allergy & Crit Care, Atlanta, GA 30322 USA
[6] London Hlth Sci Ctr, London, ON, Canada
[7] W Hertfordshire Hlth Trust, Hemel Hempstead, Herts, England
[8] Hosp Israelita Albert Einstein, Sao Paulo, Brazil
[9] Univ Lille 2, Univ Hosp Lille, Dept Anesthesiol & Intens Care, Lille, France
[10] Erasme Univ Hosp, Dept Intens Care, B-1070 Brussels, Belgium
[11] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
关键词
INTENSIVE-CARE UNITS; ORGAN DYSFUNCTION; EPIDEMIOLOGY; THERAPY; MULTICENTER; SURVIVAL; SCORE; ICU; IMPROVEMENT; MORTALITY;
D O I
10.1007/s15010-008-8203-z
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The PROGRESS Registry (Promoting Global Research Excellence in Severe Sepsis) was designed to provide comparative data reflecting everyday clinical practice, thereby allowing participating institutions to explore and benchmark medical interventions in severe sepsis. PROGRESS was an international, noninterventional, prospective, observational registry collecting data that describe the management and outcomes of severe sepsis patients in intensive care units (ICUs). Patients were enrolled who had been diagnosed with severe sepsis (suspected or proven infection and a parts per thousand yen 1 acute sepsis-induced organ dysfunction) at the participating institutions, where de-identified data were entered directly into a secured website. PROGRESS was governed by an independent international medical advisory board. PROGRESS took place in 276 ICUs in 37 countries, and 12,881 patients were identified as having severe sepsis. There was considerable variation among countries in enrollment levels, provision of standard treatment and supportive therapies, and ICU and hospital outcomes. Eight countries accounted for 65.2% of the enrolled patients. Males (59.3%) and Caucasian (48.6%) patients predominated the patient cohort. Diagnosis of severe sepsis was prior to ICU admission in 45.7% of patients, at ICU admission in 29.1% of patients, and after ICU admission in the remainder. Globally, ICU and hospital mortality rates were 39.2% and 49.6%, respectively. The mean length of ICU and hospital stay was 14.6 days and 28.2 days, respectively. The PROGRESS international sepsis registry demonstrates that a large web-based sepsis registry is feasible. Wide variations in outcomes and use of sepsis therapies were observed between countries. These results also suggest that additional opportunities exist across countries to improve severe sepsis outcomes.
引用
收藏
页码:222 / 232
页数:11
相关论文
共 43 条
[1]   Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death [J].
Abraham, E ;
Laterre, P ;
Garg, R ;
Levy, H ;
Talwar, D ;
Trzaskoma, BL ;
Francois, B ;
Guy, JS ;
Bruckmann, M ;
Rea-Neto, A ;
Rossaint, R ;
Perrotin, D ;
Sablotzki, A ;
Arkins, N ;
Utterback, BG ;
Macias, WL .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (13) :1332-1341
[2]  
*AC RESP DISTR SYN, 2000, NEW ENGL J MED, V342, P1301, DOI DOI 10.1056/NEJM200005043421801
[3]   Impact of introducing multiple evidence-based clinical practice protocols in a medical intensive care unit: A retrospective cohort study [J].
Afessa B. ;
Gajic O. ;
Keegan M.T. ;
Seferian E.G. ;
Hubmayr R.D. ;
Peters S.G. .
BMC Emergency Medicine, 7 (1)
[4]  
Agresti A., 2018, An introduction to categorical data analysis
[5]   Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study [J].
Alberti, C ;
Brun-Buisson, C ;
Burchardi, H ;
Martin, C ;
Goodman, S ;
Artigas, A ;
Sicignano, A ;
Palazzo, M ;
Moreno, R ;
Boulmé, R ;
Lepage, E ;
Le Gall, JR .
INTENSIVE CARE MEDICINE, 2002, 28 (02) :108-121
[6]   Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care [J].
Angus, DC ;
Linde-Zwirble, WT ;
Lidicker, J ;
Clermont, G ;
Carcillo, J ;
Pinsky, MR .
CRITICAL CARE MEDICINE, 2001, 29 (07) :1303-1310
[7]   Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock [J].
Annane, D ;
Sébille, V ;
Charpentier, C ;
Bollaert, PE ;
François, B ;
Korach, JM ;
Capellier, G ;
Cohen, Y ;
Azoulay, E ;
Troché, G ;
Chaumet-Riffaut, P ;
Bellissant, E .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (07) :862-871
[8]   Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709
[9]   DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ .
CHEST, 1992, 101 (06) :1644-1655
[10]  
Castro R, 2008, MINERVA ANESTESIOL, V74, P223